Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer
FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
Head-To-Head Contrast: Flora Growth (NASDAQ:FLGC) & NovoCure (NASDAQ:NVCR)
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
NovoCure: 3 Key Takeaways for Long-Term Investors
NovoCure Limited (NVCR) Q3 2026 Earnings Call Transcript
NovoCure Q3 Earnings Call Highlights
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
NovoCure (NASDAQ:NVCR) and Ambu A/S (OTCMKTS:AMBBY) Head to Head Contrast
Novocure: A Mispriced Cash-Generating Biotech With Upside Potential
Reviewing NeurAxis (NASDAQ:NRXS) and NovoCure (NASDAQ:NVCR)
Critical Survey: Medline (NASDAQ:MDLN) & NovoCure (NASDAQ:NVCR)
Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
NovoCure Limited $NVCR Stake Trimmed by Corient Private Wealth LP
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Novocure Reports Patient Data Exposure in Cybersecurity Incident
Already premium?